

Christos Kosmas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/856718/publications.pdf>

Version: 2024-02-01

113
papers

2,502
citations

218662
26
h-index

214788
47
g-index

114
all docs

114
docs citations

114
times ranked

3092
citing authors

#	ARTICLE	IF	CITATIONS
1	Posterior Reversible Encephalopathy Syndrome Associated with Oxaliplatin Use for Pancreatic Adenocarcinoma. Case Reports in Oncology, 2021, 14, 838-844.	0.7	2
2	Central neurotoxicity induced by trastuzumab emtansine (T-DM1). Anti-Cancer Drugs, 2021, Publish Ahead of Print, 1146-1149.	1.4	5
3	High grade neuroendocrine carcinoma of the breast, first line and maintenance immunotherapy. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	1.4	2
4	Perforated appendicitis induced by pembrolizumab. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	1.4	5
5	Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors. World Journal of Clinical Oncology, 2021, 12, 746-766.	2.3	5
6	An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors. Critical Reviews in Oncology/Hematology, 2021, 166, 103457.	4.4	2
7	Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab. Anti-Cancer Drugs, 2021, 32, 330-336.	1.4	4
8	Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer. Frontiers in Oncology, 2021, 11, 788809.	2.8	9
9	Plerixafor-aided Mobilization of Peripheral Blood Hematopoietic Stem Cells to Support Subsequent High-dose Chemotherapy After a Prior Autologous Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e50-e57.	0.4	1
10	Paraneoplastic hypoglycaemia secondary to IGF-2 secretion from a metastatic gastrointestinal stromal tumour. Endocrine and Metabolic Science, 2020, 1, 100047.	1.6	1
11	Clinicopathological differences and correlations between right and left colon cancer. World Journal of Clinical Cases, 2020, 8, 1424-1443.	0.8	16
12	Advanced Lung Cancer Survival in Times of Economic Hardship: A Greek Paradigm. Asian Pacific Journal of Cancer Care, 2020, 5, 19-25.	0.1	2
13	Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor. Anti-Cancer Drugs, 2019, 30, 205-208.	1.4	2
14	Re-mobilization of hematopoietic progenitors for further autografting after prior myelo-ablative high-dose chemotherapy and autologous hematopoietic stem cell transplantation; <i>the role of plerixafor</i>. Leukemia and Lymphoma, 2019, 60, 1819-1822.	1.3	1
15	Hypertestosteronemia and Infertility from a Mediastinal Extragonadal Germ Cell Tumor. American Journal of Medicine, 2017, 130, e261-e263.	1.5	3
16	Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine. Anti-Cancer Drugs, 2017, 28, 801-807.	1.4	5
17	Plerixafor mobilization of peripheral blood hematopoietic progenitors to support further high-dose chemotherapy cycles in a patient with germ-cell tumor relapsing after previous tandem high-dose chemotherapy and hematopoietic cell transplantation. Anti-Cancer Drugs, 2017, 28, 237-241.	1.4	5
18	Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients. Molecular and Clinical Oncology, 2016, 5, 440-446.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors. <i>Anti-Cancer Drugs</i> , 2014, 25, 841-847.	1.4	10
20	Complete Remission of Progressive SLE after High-dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Relapsed Non-seminomatous Germ Cell Tumor. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	1
21	Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1995-2003.	2.5	8
22	Chemotherapy ± Cetuximab Modulates Peripheral Immune Responses in Metastatic Colorectal Cancer. <i>Oncology</i> , 2013, 84, 273-283.	1.9	11
23	Control of relapsed germ cell tumor and SLE nephritis by high-dose chemotherapy and autologous hematopoietic cell transplantation. <i>Future Oncology</i> , 2013, 9, 1401-1406.	2.4	1
24	Factors Influencing Survival in Stage IV Colorectal Cancer: The Influence of DNA Ploidy. <i>ISRN Gastroenterology</i> , 2013, 2013, 1-6.	1.5	11
25	Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter Pylori infection. <i>BMC Cancer</i> , 2012, 12, 264.	2.6	20
26	Combined treatment with Bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients. <i>Investigational New Drugs</i> , 2012, 30, 395-402.	2.6	11
27	Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: A retrospective analysis. <i>European Journal of Surgical Oncology</i> , 2011, 37, 312-318.	1.0	46
28	Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient. <i>Anti-Cancer Drugs</i> , 2011, 22, 111-114.	1.4	2
29	Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours. <i>British Journal of Cancer</i> , 2011, 105, 897-902.	6.4	2
30	Successful autologous hematopoietic stem cell (AHSC) mobilization with salvage etoposide (VP16)-ifosfamide-platinum (VIP) followed by high-dose chemotherapy (HDC) and AHSC transplantation (AHSCT) in relapsed malignancies: preliminary single center experience.. <i>Journal of Clinical Oncology</i> , 2011, 29, 6540-6540.	1.6	2
31	Double high-dose chemotherapy and stem cell transplantation in adult Wilms's tumor. <i>Future Oncology</i> , 2010, 6, 1803-1809.	2.4	5
32	Phase II study of liposomal cisplatin (Lipoplatin,®) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 68, 240-247.	2.0	82
33	Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. <i>British Journal of Cancer</i> , 2009, 101, 1059-1065.	6.4	31
34	Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. <i>BMC Cancer</i> , 2009, 9, 264.	2.6	7
35	Topoisomerase I and II protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 391-398.	2.3	36
36	9088 Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 531.	2.2	16

#	ARTICLE	IF	CITATIONS
37	CEA and CA-19.9 Serum Tumor Markers as Prognostic Factors in Patients with Locally Advanced (Unresectable) or Metastatic Pancreatic Adenocarcinoma: A Retrospective Analysis. <i>Journal of Chemotherapy</i> , 2009, 21, 673-680.	1.5	19
38	Malignant peripheral nerve sheath tumor in neurofibromatosis type-1: two case reports. <i>Cases Journal</i> , 2009, 2, 7612.	0.4	4
39	Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 75-82.	2.5	281
40	Gabapentin Monotherapy for the Treatment of Chemotherapy-Induced Neuropathic Pain: A Pilot Study. <i>Pain Medicine</i> , 2008, 9, 1209-1216.	1.9	57
41	Efficacy of tropisetron in patients with advanced non-small-cell lung cancer receiving adjuvant chemotherapy with carboplatin and taxanes. <i>European Journal of Cancer Care</i> , 2008, 17, 167-173.	1.5	2
42	Treatment strategies in CNS metastases. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2087-2098.	1.8	2
43	Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. <i>Anticancer Research</i> , 2008, 28, 543-9.	1.1	38
44	Docetaxel-Ifosfamide Combination in Patients with Advanced Breast Cancer Failing Prior Anthracycline- Based Regimens: Results of a Phase I-II Study. <i>Journal of Chemotherapy</i> , 2007, 19, 322-331.	1.5	3
45	Sequential Administration of 5-Fluorouracil (5FU)/Leucovorin (LV) Followed by Irinotecan (CPT-11) at Relapse versus CPT-11 Followed by 5-FU/LV in Advanced Colorectal Carcinoma. <i>Chemotherapy</i> , 2007, 53, 282-291.	1.6	14
46	Rare and aggressive metastatic, axial multifocal local epithelioid sarcoma associated with paraneoplastic granulocytosis and hypoglycaemia. <i>Lancet Oncology</i> , The, 2007, 8, 82-84.	10.7	8
47	Comparison of two oral regimens for the outpatient treatment of low-risk cancer patients with chemotherapy-induced neutropenia and fever: Ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus amoxicillin/clavulanate. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 786-791.	1.5	6
48	Docetaxel- ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. <i>Investigational New Drugs</i> , 2007, 25, 463-470.	2.6	2
49	Spontaneous remission of acute myeloid leukemia associated with GnRH agonist treatment. <i>Leukemia and Lymphoma</i> , 2006, 47, 557-560.	1.3	7
50	Analgesic activity of high-dose intravenous calcitonin in cancer patients with bone metastases. <i>Oncology Reports</i> , 2006, 16, 871.	2.6	5
51	Diffuse Calcification of Metastases after Intensive Multiagent Chemotherapy in Widespread Osteosarcoma Leading to Death in a 18-Year-Old Male: Report of a Case and Literature Review. <i>Medical Oncology</i> , 2006, 23, 455-462.	2.5	0
52	A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane+Platinum-based regimens. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 59, 51-59.	2.3	20
53	Intramedullary Spinal Cord Metastases from Atypical Small Cell Lung Cancer: A Case Report and Literature Review. <i>Cancer Investigation</i> , 2006, 24, 46-49.	1.3	20
54	Methotrexate-Paclitaxel-Epirubicin-Carboplatin (M-TEC) Combination Chemotherapy in Patients with Advanced Bladder Cancer: An Open Label Phase II Study. <i>Journal of Chemotherapy</i> , 2005, 17, 444-448.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Changes of Cerebrospinal Fluid Tumor Marker Levels May Predict Response to Treatment and Survival of Carcinomatous Meningitis in Patients with Advanced Breast Cancer. <i>Medical Oncology</i> , 2005, 22, 123-128.	2.5	12
56	A Phase II Study of the Docetaxel+Carboplatin Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer. <i>Lung</i> , 2005, 183, 405-416.	3.3	5
57	Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. <i>Investigational New Drugs</i> , 2005, 23, 369-375.	2.6	99
58	Intramedullary spinal cord metastases in breast cancer: report of four cases and review of the literature. <i>Journal of Neuro-Oncology</i> , 2005, 71, 67-72.	2.9	35
59	A Phase II Study of the Docetaxel- Ifosfamide-Carboplatin Combination in Advanced Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2005, 69, 333-341.	1.9	2
60	Retinol-binding protein, acute phase reactants and <i>Helicobacter pylori</i> infection in patients with gastric adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2005, 11, 7174.	3.3	14
61	The Effect of Edrecolomab (Mo17-1A) or Fluorouracil-Based Chemotherapy on Specific Immune Parameters in Patients with Colorectal Cancer. <i>Oncology</i> , 2004, 67, 403-410.	1.9	3
62	Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer. <i>Investigational New Drugs</i> , 2004, 22, 193-198.	2.6	89
63	Weekly Gemcitabine plus Fluorouracil-Folinic Acid Given Weekly for Two Days in Patients with Advanced Pancreatic Cancer. <i>Clinical Drug Investigation</i> , 2004, 24, 661-670.	2.2	7
64	Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer. <i>Oncology Reports</i> , 2004, 12, 927-32.	2.6	4
65	Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: Examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer. <i>Oncology Reports</i> , 2004, 11, 899-903.	2.6	2
66	Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 514-519.	2.3	25
67	Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. <i>Journal of Pain and Symptom Management</i> , 2003, 26, 849-854.	1.2	6
68	A unique case of splenic marginal zone-cell lymphoma with synchronous clonal T-cell large granular lymphocyte proliferation: an immunologic, immunohistochemical and genotypic study. <i>Leukemia Research</i> , 2003, 27, 85-87.	0.8	11
69	An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 265-275.	4.4	17
70	Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. <i>Annals of Oncology</i> , 2003, 14, 537-542.	1.2	23
71	Absence of chemotherapy-induced alopecia with paclitaxel in a case of hypothyroidism: case report. <i>Annals of Oncology</i> , 2003, 14, 1690-1691.	1.2	3
72	Phase II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. <i>British Journal of Cancer</i> , 2003, 88, 1168-1174.	6.4	10

#	ARTICLE	IF	CITATIONS
73	Full Dose Paclitaxel Plus Vinorelbine as Salvage Chemotherapy in Anthracycline-Resistant Advanced Breast Cancer: A Phase II Study. <i>Journal of Chemotherapy</i> , 2003, 15, 607-612.	1.5	19
74	Somatic Hypermutation Patterns in Germinal Center B Cell Malignancies. <i>Hematology</i> , 2003, 8, 319-328.	1.5	7
75	Immune Changes in Patients with Colorectal Cancer Treated by Adjuvant Therapy with Monoclonal Antibody 17-1 A: A Pilot Study. <i>Journal of Chemotherapy</i> , 2003, 15, 387-393.	1.5	4
76	Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study. <i>Anticancer Research</i> , 2003, 23, 4205-11.	1.1	13
77	Etoposide, Leucovorin (LV) and 5-Fluorouracil (5-FU) in 5-FU+LV Pre-Treated Patients with Advanced Colorectal Cancer. <i>Journal of Chemotherapy</i> , 2002, 14, 406-411.	1.5	2
78	Glycosylation of V region genes in follicular lymphoma as a result of the somatic hypermutation mechanism. <i>Blood</i> , 2002, 100, 2269-2270.	1.4	1
79	Absence of Somatic Hypermutation in the Open Reading Frame of the Bcl-2 Gene Participating in the t(14;18) Chromosomal Translocation in Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 2391-2393.	1.3	1
80	Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. <i>BMC Cancer</i> , 2002, 2, 2.	2.6	10
81	A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2002, 98, 141-147.	5.1	12
82	Anti-CD20-based therapy of B cell lymphoma: state of the art. <i>Leukemia</i> , 2002, 16, 2004-2015.	7.2	58
83	Clonal T-large granular lymphocyte proliferations associated with clonal B cell lymphoproliferative disorders: report of eight cases. <i>Leukemia</i> , 2002, 16, 2167-2169.	7.2	33
84	Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. <i>British Journal of Cancer</i> , 2002, 87, 21-27.	6.4	283
85	Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study. <i>Investigational New Drugs</i> , 2002, 20, 133-136.	2.6	3
86	Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer. <i>Journal of Neuro-Oncology</i> , 2002, 56, 265-273.	2.9	19
87	Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer. <i>Medical Science Monitor</i> , 2002, 8, Pl65-9.	1.1	1
88	Phase II Study of Paclitaxel, Ifosfamide, and Cisplatin as Second-Line Treatment in Relapsed Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 119-126.	1.6	61
89	Comparative Study of Tropisetron with the Addition of Dexamethasone or Alprazolam in Breast Cancer Patients Receiving Adjuvant Chemotherapy with CEF (Cyclophosphamide, Epirubicin and) Tj ETQq1 1 0.7843.54 rgBT /Overlock 1		
90	Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. <i>Cancer</i> , 2001, 92, 2902-2910.	4.1	36

#	ARTICLE	IF	CITATIONS
91	Extragenital Seminoma After Renal Transplantation and Immunosuppression; Treatment in the Presence of Renal Dysfunction. <i>Medical Oncology</i> , 2001, 18, 221-226.	2.5	2
92	Hypersensitivity Reactions to Carboplatin Administration Are Common but Not Always Severe: A 10-Year Experience. <i>Oncology</i> , 2001, 61, 129-133.	1.9	133
93	A Phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2000, 89, 774-782.	4.1	19
94	Molecular insights into the immunopathogenesis of follicular lymphoma. <i>Trends in Immunology</i> , 2000, 21, 298-305.	7.5	66
95	Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. <i>British Journal of Cancer</i> , 2000, 82, 300-307.	6.4	20
96	Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. <i>Annals of Oncology</i> , 1999, 10, 211-216.	1.2	82
97	Molecular analysis of bcl-1/IgH junctional sequences in mantle cell lymphoma: potential mechanism of the t(11;14) chromosomal translocation. <i>British Journal of Haematology</i> , 1999, 105, 190-197.	2.5	28
98	Molecular Analysis of Immunoglobulin Genes in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1999, 33, 253-265.	1.3	15
99	Second-Line Chemotherapy with Cisplatin-Ifosfamide in Patients with Ovarian Cancer Previously Treated with Carboplatin-Cyclophosphamide. <i>Journal of Chemotherapy</i> , 1999, 11, 144-149.	1.5	5
100	Somatic hypermutation of immunoglobulin variable region genes: focus on follicular lymphoma and multiple myeloma. <i>Immunological Reviews</i> , 1998, 162, 281-292.	6.0	38
101	Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 509-511.	2.3	29
102	Monoclonal Antibody Targeting of Ovarian Carcinoma. <i>Oncology</i> , 1998, 55, 435-446.	1.9	15
103	A feasibility study of 1-h paclitaxel infusion in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 40, 353-357.	2.3	13
104	t(14;18) chromosomal translocation in follicular lymphoma: an event occurring with almost equal frequency both at the D to JH and at later stages in the rearrangement process of the immunoglobulin heavy chain gene locus. <i>British Journal of Haematology</i> , 1997, 99, 866-872.	2.5	19
105	Follicular lymphoma immunoglobulin κ light chains are affected by the antigen selection process, but to a lesser degree than their partner heavy chains. <i>British Journal of Haematology</i> , 1997, 96, 132-146.	2.5	56
106	Analysis of the κ light chain variable region in multiple myeloma. <i>British Journal of Haematology</i> , 1996, 94, 306-317.	2.5	27
107	5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer. <i>Anti-Cancer Drugs</i> , 1995, 6, 599-603.	1.4	2
108	Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. <i>Cancer</i> , 1994, 73, 3000-3010.	4.1	28

#	ARTICLE	IF	CITATIONS
109	Review: Advances in Monoclonal Antibody Tumour Targeting. Journal of Drug Targeting, 1993, 1, 81-91.	4.4	16
110	Effects of Phorbol Esters and Cytokines (Interleukin-2,-4, and -6) on the Proliferation and Surface Phenotype of Epstein-Barr Virus Immortalised Human B Lymphocytes. Leukemia and Lymphoma, 1992, 8, 109-115.	1.3	1
111	Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. British Journal of Cancer, 1991, 64, 911-914.	6.4	38
112	Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. British Journal of Cancer, 1991, 64, 494-500.	6.4	16
113	Monoclonal antibodies for imaging and therapy. British Journal of Cancer, 1989, 59, 152-155.	6.4	30